首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound
【2h】

Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound

机译:DA-PLGA-PEG-cRGD纳米粒子联合超声预防氧化型低密度脂蛋白诱导的内皮细胞损伤

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In general, atherosclerosis is considered to be a form of chronic inflammation. Dexamethasone has anti-inflammatory effects in atherosclerosis, but it was not considered for long-term administration on account of a poor pharmacokinetic profile and adverse side effects. Nanoparticles in which drugs can be dissolved, encapsulated, entrapped or chemically attached to the particle surface have abilities to incorporate dexamethasone and to be used as controlled or targeted drug delivery system. Long circulatory polymeric nanoparticles present as an assisting approach for controlled and targeted release of the encapsulated drug at the atherosclerotic site. Polymeric nanoparticles combined with ultrasound (US) are widely applied in cancer treatment due to their time applications, low cost, simplicity, and safety. However, there are few studies on atherosclerosis treatment using polymeric nanoparticles combined with US. In this study, targeted dexamethasone acetate (DA)-loaded poly (lactide-glycolide)-polyethylene glycol-cRGD (PLGA-PEG-cRGD) nanoparticles (DA-PLGA-PEG-cRGD NPs) were prepared by the emulsion-evaporation method using cRGD modified PLGA-PEG polymeric materials (PLGA-PEG-cRGD) prepared as the carrier. The average particle size of DA-PLGA-PEG-cRGD NPs was 221.6 ± 0.9 nm. Morphology of the nanoparticles was spherical and uniformly dispersed. In addition, the DA released profiles suggested that ultrasound could promote drug release from the nanocarriers and accelerate the rate of release. In vitro, the cellular uptake process of fluorescein isothiocyanate (FITC)@DA-PLGA-PEG-cRGD NPs combined with US into the damaged human umbilical vein endothelial cells (HUVECs) indicated that US promoted rapid intracellular uptake of FITC@DA- PLGA-PEG-cRGD NPs. The cell viability of DA-PLGA-PEG-cRGD NPs combined with US reached 91.9% ± 0.2%, which demonstrated that DA-PLGA-PEG-cRGD NPs combined with US had a positive therapeutic effect on damaged HUVECs. Overall, DA-PLGA-PEG-cRGD NPs in combination with US may provide a promising drug delivery system to enhance the therapeutic effects of these chemotherapeutics at the cellular level.
机译:通常,动脉粥样硬化被认为​​是慢性炎症的一种形式。地塞米松在动脉粥样硬化中具有抗炎作用,但由于药代动力学不良和不良副作用,因此并未考虑长期服用。可以将药物溶解,包裹,包埋或化学附着到颗粒表面的纳米颗粒具有掺入地塞米松并可用作受控或靶向药物输送系统的能力。长循环聚合物纳米颗粒作为在动脉粥样硬化部位控制和靶向释放封装药物的辅助方法而存在。聚合纳米颗粒与超声(美国)相结合,由于其应用时间短,成本低,简单和安全性而被广泛应用于癌症治疗。然而,很少有研究使用聚合物纳米颗粒与US联合治疗动脉粥样硬化。在这项研究中,通过乳液蒸发法使用以下方法制备了靶向醋酸地塞米松(DA)负载的聚(丙交酯-乙交酯)-聚乙二醇-cRGD(PLGA-PEG-cRGD)纳米颗粒(DA-PLGA-PEG-cRGD NP)。将cRGD改性的PLGA-PEG聚合材料(PLGA-PEG-cRGD)制成载体。 DA-PLGA-PEG-cRGD NP的平均粒径为221.6±0.9 nm。纳米颗粒的形态为球形且均匀分散。此外,DA释放曲线表明超声可以促进药物从纳米载体释放并加快释放速率。在体外,异硫氰酸荧光素(FITC)@ DA-PLGA-PEG-cRGD NPs与US结合进入受损的人脐静脉内皮细胞(HUVEC)的细胞摄取过程表明,US促进了FITC @ DA-PLGA-的快速细胞内摄取。 PEG-cRGD NP。 DA-PLGA-PEG-cRGD NPs与US结合后的细胞存活率达到91.9%±0.2%,这表明DA-PLGA-PEG-cRGD NPs与US结合对受损的HUVEC具有积极的治疗作用。总体而言,DA-PLGA-PEG-cRGD NP与US结合可提供一种有希望的药物递送系统,以增强这些化学疗法在细胞水平上的治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号